Isao Taguchi - Academia.edu (original) (raw)
Papers by Isao Taguchi
Circulation, Jan 8, 2018
Current guidelines call for high-intensity statin therapy in patients with cardiovascular disease... more Current guidelines call for high-intensity statin therapy in patients with cardiovascular disease on the basis of several previous "more versus less statins" trials. However, no clear evidence for more versus less statins has been established in an Asian population. In this prospective, multicenter, randomized, open-label, blinded end point study, 13 054 Japanese patients with stable coronary artery disease who achieved low-density lipoprotein cholesterol (LDL-C) <120 mg/dL during a run-in period (pitavastatin 1 mg/d) were randomized in a 1-to-1 fashion to high-dose (pitavastatin 4 mg/d; n=6526) or low-dose (pitavastatin 1 mg/d; n=6528) statin therapy. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization. The secondary composite end point was a composite of the primary end point and clinically indicated coronary revascularization excluding target-le...
Hypertension research : official journal of the Japanese Society of Hypertension, Jan 14, 2016
Cardiovascular diabetology, 2016
Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular ... more Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular diseases, the number of patients with diabetes with chronic heart failure is increasing steadily. However, clinical evidence of therapeutic strategies in such patients is still lacking. A recent randomized, placebo-controlled trial in patients with type 2 diabetes with high cardiovascular risk demonstrated that the SGLT2 inhibitor, empagliflozin, reduced the incidence of hospitalization for heart failure. Because SGLT2 inhibitors cause a reduction in body weight and blood pressure in addition to improving glycemic control, they have the potential to exert beneficial effects on the clinical pathophysiology of heart failure. The aim of the ongoing CANDLE trial is to test the safety and non-inferiority of canagliflozin, another SGLT2 inhibitor, compared with glimepiride, a sulfonylurea agent, in patients with type 2 diabetes mellitus and chronic heart failure. A total of 250 patients with t...
Circulation, Nov 22, 2011
Circulation, Nov 26, 2013
Journal of Physics C Solid State Physics, Aug 10, 1981
Circulation Journal Official Journal of the Japanese Circulation Society, Jan 25, 2013
International Journal of Oncology, Nov 1, 2001
Journal of Cardiovascular Electrophysiology, 2015
Journal of cardiovascular electrophysiology, Jan 4, 2016
Atrial low-voltage zones (LVZs) may be related to maintenance of atrial fibrillation (AF). The in... more Atrial low-voltage zones (LVZs) may be related to maintenance of atrial fibrillation (AF). The influence of left atrial (LA) contact areas (CoAs) on reentrant or rotor-like sources maintaining AF has not been investigated. Forty patients with persistent AF (PsAF) were analyzed. Three representative CoA regions in the LA (ascending aorta: anterior wall; descending aorta: left inferior pulmonary vein; and vertebrae: posterior wall) were visualized by enhanced CT. Using circular catheters, the LVZs (<0.5 mV) were assessed after restoration of SR, and local activation mapping and frequency domain analyses were performed after induction of AF. Circular activation during AF was visually defined as sites with ≥ 2 rotations by serial electrograms encompassing >80% of the mean AF cycle length. A pivot was defined as the core of the localized circular activation. Anterior (39/40 patients, 98%), left pulmonary vein antrum (27/40, 68%), and posterior (19/40, 48%) CoAs were identified, and...
Circulation, Nov 20, 2012
J Clin Pharm Ther, 2010
What is known and objective: Telmisartan, an angiotensin II type 1 receptor blocker (ARB), acts a... more What is known and objective: Telmisartan, an angiotensin II type 1 receptor blocker (ARB), acts as a partial agonist for peroxisome proliferatoractivated receptor-c, and thus improves abnormalities of glucose metabolism and hypertriglyceridaemia in addition to its documented blood pressure-lowering effects. Recently, it has been demonstrated that telmisartan also lowers the levels of total cholesterol and low-density lipoprotein (LDL) cholesterol levels. This study was designed to investigate the mechanism of cholesterol reduction. Methods: We measured serum levels of cholestanol, a cholesterol absorption marker, and lathosterol, a cholesterol synthesis marker, in 20 patients with both hypercholesterolaemia and hypertension. Ten patients were treated with telmisartan and the remaining 10 with fluvastatin. Results: After 3 months of treatment, total and LDL cholesterol levels decreased in the telmisartan group (P < 0AE01 for both total and LDL cholesterol levels) and the fluvastatin group (P < 0AE001 for both total and LDL cholesterol levels). The change in cholestanol level after 3 months of treatment was positively correlated with the levels of total (R = 0AE72, P < 0AE05) and LDL cholesterol (R = 0AE81, P < 0AE01) in the telmisartan group. The change in lathosterol level was positively correlated with the levels of total (R = 0AE88, P = 0AE001) and LDL cholesterol (R = 0AE89, P = 0AE001) in the fluvastatin group.
Heart, lung & circulation, Jan 18, 2015
The impact of obstructive sleep apnoea on heart failure with preserved ejection fraction is unkno... more The impact of obstructive sleep apnoea on heart failure with preserved ejection fraction is unknown. Fifty-eight patients who had heart failure with a left ventricular ejection fraction; ≥50% underwent a sleep study. Brain natriuretic peptide (BNP) levels were determined at enrolment and at one, six, 12 and 36 months after enrolment. Obstructive sleep apnoea was found in 39 patients (67%), and they were all subsequently treated with continuous positive airway pressure. Echocardiography at admission showed that E/E' tended to be higher in the 39 patients with, than in the 19 patients without, obstructive sleep apnoea (15.0±3.6 vs 12.1±1.9, respectively, P=0.05). The median BNP levels at enrolment were similar in patients with and without obstructive sleep apnoea [median (interquartile range): 444 (233-752) vs 316 (218-703) pg/ml]. Although BNP levels decreased over time in both groups, the reduction was less pronounced in patients with obstructive sleep apnoea (P<0.05). Conseq...
Dokkyo Journal of Medical Sciences, Oct 25, 2008
Circulation Journal Official Journal of the Japanese Circulation Society, Mar 1, 2009
Circulation, Nov 26, 2013
Dokkyo Journal of Medical Sciences, Mar 25, 2014
Circulation, Nov 25, 2014
Circulation
Background: Whole coronary artery treatment is very important to improve prognosis of acute coron... more Background: Whole coronary artery treatment is very important to improve prognosis of acute coronary syndrome (ACS) after early reperfusion of culprit lesions. Early statin treatment led residual lesion plaques beyond culprit lesions to regress in ACS patients. However, precise mechanism of plaque stabilization is not well known. Purpose: We aimed that the evaluation of the plaque composition changes in progression or regression phases by virtual histology-intravascular ultrasound (VH-IVUS) under strong statin treatment. Method: We studied effects of statins (pitavastatin 2 mg/day or atorvastatin 10 mg/day) on stabilizing coronary plaque beyond culprit lesions in 106 ACS patients, using VH-IVUS evaluation of a non-culprit lesion at admission (baseline), at short-term (2-3 weeks) and at middle-term (8-10 months). According to the plaque volume change from baseline to middle-term IVUS evaluation, subjects were divided into 2 groups, plaque regression group (n=87) and plaque progressio...
Circulation, Jan 8, 2018
Current guidelines call for high-intensity statin therapy in patients with cardiovascular disease... more Current guidelines call for high-intensity statin therapy in patients with cardiovascular disease on the basis of several previous "more versus less statins" trials. However, no clear evidence for more versus less statins has been established in an Asian population. In this prospective, multicenter, randomized, open-label, blinded end point study, 13 054 Japanese patients with stable coronary artery disease who achieved low-density lipoprotein cholesterol (LDL-C) <120 mg/dL during a run-in period (pitavastatin 1 mg/d) were randomized in a 1-to-1 fashion to high-dose (pitavastatin 4 mg/d; n=6526) or low-dose (pitavastatin 1 mg/d; n=6528) statin therapy. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization. The secondary composite end point was a composite of the primary end point and clinically indicated coronary revascularization excluding target-le...
Hypertension research : official journal of the Japanese Society of Hypertension, Jan 14, 2016
Cardiovascular diabetology, 2016
Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular ... more Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular diseases, the number of patients with diabetes with chronic heart failure is increasing steadily. However, clinical evidence of therapeutic strategies in such patients is still lacking. A recent randomized, placebo-controlled trial in patients with type 2 diabetes with high cardiovascular risk demonstrated that the SGLT2 inhibitor, empagliflozin, reduced the incidence of hospitalization for heart failure. Because SGLT2 inhibitors cause a reduction in body weight and blood pressure in addition to improving glycemic control, they have the potential to exert beneficial effects on the clinical pathophysiology of heart failure. The aim of the ongoing CANDLE trial is to test the safety and non-inferiority of canagliflozin, another SGLT2 inhibitor, compared with glimepiride, a sulfonylurea agent, in patients with type 2 diabetes mellitus and chronic heart failure. A total of 250 patients with t...
Circulation, Nov 22, 2011
Circulation, Nov 26, 2013
Journal of Physics C Solid State Physics, Aug 10, 1981
Circulation Journal Official Journal of the Japanese Circulation Society, Jan 25, 2013
International Journal of Oncology, Nov 1, 2001
Journal of Cardiovascular Electrophysiology, 2015
Journal of cardiovascular electrophysiology, Jan 4, 2016
Atrial low-voltage zones (LVZs) may be related to maintenance of atrial fibrillation (AF). The in... more Atrial low-voltage zones (LVZs) may be related to maintenance of atrial fibrillation (AF). The influence of left atrial (LA) contact areas (CoAs) on reentrant or rotor-like sources maintaining AF has not been investigated. Forty patients with persistent AF (PsAF) were analyzed. Three representative CoA regions in the LA (ascending aorta: anterior wall; descending aorta: left inferior pulmonary vein; and vertebrae: posterior wall) were visualized by enhanced CT. Using circular catheters, the LVZs (<0.5 mV) were assessed after restoration of SR, and local activation mapping and frequency domain analyses were performed after induction of AF. Circular activation during AF was visually defined as sites with ≥ 2 rotations by serial electrograms encompassing >80% of the mean AF cycle length. A pivot was defined as the core of the localized circular activation. Anterior (39/40 patients, 98%), left pulmonary vein antrum (27/40, 68%), and posterior (19/40, 48%) CoAs were identified, and...
Circulation, Nov 20, 2012
J Clin Pharm Ther, 2010
What is known and objective: Telmisartan, an angiotensin II type 1 receptor blocker (ARB), acts a... more What is known and objective: Telmisartan, an angiotensin II type 1 receptor blocker (ARB), acts as a partial agonist for peroxisome proliferatoractivated receptor-c, and thus improves abnormalities of glucose metabolism and hypertriglyceridaemia in addition to its documented blood pressure-lowering effects. Recently, it has been demonstrated that telmisartan also lowers the levels of total cholesterol and low-density lipoprotein (LDL) cholesterol levels. This study was designed to investigate the mechanism of cholesterol reduction. Methods: We measured serum levels of cholestanol, a cholesterol absorption marker, and lathosterol, a cholesterol synthesis marker, in 20 patients with both hypercholesterolaemia and hypertension. Ten patients were treated with telmisartan and the remaining 10 with fluvastatin. Results: After 3 months of treatment, total and LDL cholesterol levels decreased in the telmisartan group (P < 0AE01 for both total and LDL cholesterol levels) and the fluvastatin group (P < 0AE001 for both total and LDL cholesterol levels). The change in cholestanol level after 3 months of treatment was positively correlated with the levels of total (R = 0AE72, P < 0AE05) and LDL cholesterol (R = 0AE81, P < 0AE01) in the telmisartan group. The change in lathosterol level was positively correlated with the levels of total (R = 0AE88, P = 0AE001) and LDL cholesterol (R = 0AE89, P = 0AE001) in the fluvastatin group.
Heart, lung & circulation, Jan 18, 2015
The impact of obstructive sleep apnoea on heart failure with preserved ejection fraction is unkno... more The impact of obstructive sleep apnoea on heart failure with preserved ejection fraction is unknown. Fifty-eight patients who had heart failure with a left ventricular ejection fraction; ≥50% underwent a sleep study. Brain natriuretic peptide (BNP) levels were determined at enrolment and at one, six, 12 and 36 months after enrolment. Obstructive sleep apnoea was found in 39 patients (67%), and they were all subsequently treated with continuous positive airway pressure. Echocardiography at admission showed that E/E' tended to be higher in the 39 patients with, than in the 19 patients without, obstructive sleep apnoea (15.0±3.6 vs 12.1±1.9, respectively, P=0.05). The median BNP levels at enrolment were similar in patients with and without obstructive sleep apnoea [median (interquartile range): 444 (233-752) vs 316 (218-703) pg/ml]. Although BNP levels decreased over time in both groups, the reduction was less pronounced in patients with obstructive sleep apnoea (P<0.05). Conseq...
Dokkyo Journal of Medical Sciences, Oct 25, 2008
Circulation Journal Official Journal of the Japanese Circulation Society, Mar 1, 2009
Circulation, Nov 26, 2013
Dokkyo Journal of Medical Sciences, Mar 25, 2014
Circulation, Nov 25, 2014
Circulation
Background: Whole coronary artery treatment is very important to improve prognosis of acute coron... more Background: Whole coronary artery treatment is very important to improve prognosis of acute coronary syndrome (ACS) after early reperfusion of culprit lesions. Early statin treatment led residual lesion plaques beyond culprit lesions to regress in ACS patients. However, precise mechanism of plaque stabilization is not well known. Purpose: We aimed that the evaluation of the plaque composition changes in progression or regression phases by virtual histology-intravascular ultrasound (VH-IVUS) under strong statin treatment. Method: We studied effects of statins (pitavastatin 2 mg/day or atorvastatin 10 mg/day) on stabilizing coronary plaque beyond culprit lesions in 106 ACS patients, using VH-IVUS evaluation of a non-culprit lesion at admission (baseline), at short-term (2-3 weeks) and at middle-term (8-10 months). According to the plaque volume change from baseline to middle-term IVUS evaluation, subjects were divided into 2 groups, plaque regression group (n=87) and plaque progressio...